Pionyr Immunotherapeutics racks up $62 mln Series B

Pionyr Immunotherapeutics Inc, a developer of antibody therapeutics, has raised $62 million in Series B funding. New Enterprise Associates led the round with participation from other investors that included Sofinnova Ventures, Vida Ventures, OrbiMed, SV Health Investors, Osage University Partners and Mission Bay Ventures.

North AmericaUSBriefs